These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 30251865

  • 1. Noninvasive Detection of HER2 Expression in Gastric Cancer by 64Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients.
    Guo X, Zhu H, Zhou N, Chen Z, Liu T, Liu F, Xu X, Jin H, Shen L, Gao J, Yang Z.
    Mol Pharm; 2018 Nov 05; 15(11):5174-5182. PubMed ID: 30251865
    [Abstract] [Full Text] [Related]

  • 2. Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies.
    Woo SK, Jang SJ, Seo MJ, Park JH, Kim BS, Kim EJ, Lee YJ, Lee TS, An GI, Song IH, Seo Y, Kim KI, Kang JH.
    J Nucl Med; 2019 Jan 05; 60(1):26-33. PubMed ID: 29777007
    [Abstract] [Full Text] [Related]

  • 3. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab.
    Al-Saden N, Lam K, Chan C, Reilly RM.
    Mol Pharm; 2018 Aug 06; 15(8):3383-3393. PubMed ID: 29957952
    [Abstract] [Full Text] [Related]

  • 4. 64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
    Kwon LY, Scollard DA, Reilly RM.
    Mol Pharm; 2017 Feb 06; 14(2):492-501. PubMed ID: 28049295
    [Abstract] [Full Text] [Related]

  • 5. Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients.
    Guo X, Zhou N, Chen Z, Liu T, Xu X, Lei X, Shen L, Gao J, Yang Z, Zhu H.
    Gastric Cancer; 2020 Jul 06; 23(4):614-626. PubMed ID: 31919745
    [Abstract] [Full Text] [Related]

  • 6. Preclinical Evaluation of [64Cu]NOTA-CP01 as a PET Imaging Agent for Metastatic Esophageal Squamous Cell Carcinoma.
    Peng T, Wang X, Li Z, Bi L, Gao J, Yang M, Wang Y, Yao X, Shan H, Jin H.
    Mol Pharm; 2021 Sep 06; 18(9):3638-3648. PubMed ID: 34424706
    [Abstract] [Full Text] [Related]

  • 7. Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
    Lam K, Chan C, Reilly RM.
    MAbs; 2017 Jan 06; 9(1):154-164. PubMed ID: 27813707
    [Abstract] [Full Text] [Related]

  • 8. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients.
    Liu J, Guo X, Wen L, Wang L, Liu F, Song G, Zhu H, Zhou N, Yang Z.
    Eur J Nucl Med Mol Imaging; 2023 Jul 06; 50(9):2775-2786. PubMed ID: 37093312
    [Abstract] [Full Text] [Related]

  • 9. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
    England CG, Jiang D, Hernandez R, Sun H, Valdovinos HF, Ehlerding EB, Engle JW, Yang Y, Huang P, Cai W.
    Mol Pharm; 2017 Oct 02; 14(10):3239-3247. PubMed ID: 28825843
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer.
    Pougoue Ketchemen J, Njotu FN, Babeker H, Ahenkorah S, Tikum AF, Nwangele E, Henning N, Cleeren F, Fonge H.
    Eur J Nucl Med Mol Imaging; 2024 Jun 02; 51(7):2070-2084. PubMed ID: 38376808
    [Abstract] [Full Text] [Related]

  • 11. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
    Persson M, Nedergaard MK, Brandt-Larsen M, Skovgaard D, Jørgensen JT, Michaelsen SR, Madsen J, Lassen U, Poulsen HS, Kjaer A.
    J Nucl Med; 2016 Feb 02; 57(2):272-8. PubMed ID: 26429955
    [Abstract] [Full Text] [Related]

  • 12. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S, Laverman P, Rosik D, Boschetti F, van der Graaf WT, Oyen WJ, van Laarhoven HW, Tolmachev V, Boerman OC.
    J Nucl Med; 2012 Jan 02; 53(1):146-53. PubMed ID: 22173842
    [Abstract] [Full Text] [Related]

  • 13. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.
    Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV, Ailles L, Hedley DW, Reilly RM.
    Mol Pharm; 2019 Aug 05; 16(8):3559-3568. PubMed ID: 31242384
    [Abstract] [Full Text] [Related]

  • 14. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA.
    J Nucl Med; 2014 Jan 05; 55(1):23-9. PubMed ID: 24337604
    [Abstract] [Full Text] [Related]

  • 15. Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model.
    Kristensen LK, Christensen C, Jensen MM, Agnew BJ, Schjöth-Frydendahl C, Kjaer A, Nielsen CH.
    Theranostics; 2019 Jan 05; 9(15):4409-4420. PubMed ID: 31285769
    [Abstract] [Full Text] [Related]

  • 16. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of 64Cu-Trastuzumab.
    Ren Q, Mohri K, Warashina S, Wada Y, Watanabe Y, Mukai H.
    Mol Pharm; 2019 Mar 04; 16(3):1065-1073. PubMed ID: 30633529
    [Abstract] [Full Text] [Related]

  • 17. 18F-Alanine Derivative Serves as an ASCT2 Marker for Cancer Imaging.
    Liu H, Han Y, Li J, Qin M, Fu Q, Wang C, Liu Z.
    Mol Pharm; 2018 Mar 05; 15(3):947-954. PubMed ID: 29308900
    [Abstract] [Full Text] [Related]

  • 18. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM.
    Nucl Med Biol; 2015 Feb 05; 42(2):71-7. PubMed ID: 25456837
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.